Impact Biomedical (IBO) FCF Margin (2025 - 2026)
Impact Biomedical's (IBO) quarterly FCF Margin came in at 6628.57% in Q1 2026, down 94.64% on a QoQ basis from 3405.56% in Q3 2025.
Impact Biomedical (IBO) FCF Margin (2025 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 2 years of FCF Margin data on file, last reported at 6628.57% in Q1 2026.
- Quarterly FCF Margin changed N/A year-over-year to 6628.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5225.0% (changed N/A YoY) and the FY2022 annual result came in at 5036.0%, changed N/A from the prior year.
- FCF Margin slipped to 6628.57% in Q1 2026, from 3405.56% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 3405.56% in Q3 2025 to a low of 9914.29% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Impact Biomedical | 49.45 Mn | 49.44 Mn | 2,000.00 | 15,666.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15,666.67% |
| Mar 31, 2026 | -6,628.57% |
| Sep 30, 2025 | -3,405.56% |
| Jun 30, 2025 | -9,914.29% |